Pathological complete response and accelerated drug approval in early breast cancer.

作者信息

Prowell Tatiana M, Pazdur Richard

机构信息

Office of Hematology Oncology Products, Food and Drug Administration, Silver Spring, MD, USA.

出版信息

N Engl J Med. 2012 Jun 28;366(26):2438-41. doi: 10.1056/NEJMp1205737. Epub 2012 May 30.

DOI:10.1056/NEJMp1205737

PMID:22646508

Abstract

摘要

相似文献

[1]

Pathological complete response and accelerated drug approval in early breast cancer.

N Engl J Med. 2012-6-28

[2]

Better prioritization may speed approval of adjuvant therapies in breast cancer.

J Natl Cancer Inst. 2008-6-18

[3]

Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.

Clin Cancer Res. 2005-8-15

[4]

Swimming upstream: an advocate reflects on cancer research and social realities.

J Clin Oncol. 2008-6-1

[5]

FDA advisors recommend approval of taxol for node-positive breast cancer.

Oncologist. 1999

[6]

High-dose chemotherapy with autologous stem-cell support in the treatment of high-risk, primary breast cancer.

Tecnologica MAP Suppl. 1999-1

[7]

FDA approves new drug for specific type of advanced breast cancer.

Mayo Clin Womens Healthsource. 2007-10

[8]

Bioregulatory niches in breast cancer.

Clin Breast Cancer. 2006-8

[9]

Dual-action drug approved for use in advanced breast cancer.

ONS Connect. 2007-6

[10]

Femara approved as first-line breast cancer therapy.

FDA Consum. 2001

引用本文的文献

[1]

Tumor infiltration therapy: from FDA approval to next-generation approaches.

Clin Exp Med. 2025-7-18

[2]

Liquid biopsy in advanced and metastatic breast cancer: translating prognostic value to clinical implementation.

Transl Cancer Res. 2025-4-30

[3]

Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response.

Transl Oncol. 2025-7

[4]

Prognostic value of residual cancer burden after neoadjuvant chemotherapy in breast cancer: a comprehensive subtype-specific analysis.

Sci Rep. 2025-4-22

[5]

Histopathologic Grading of Residual Tumor Predicts Survival of Intrahepatic Cholangiocarcinoma Patients Treated With Neoadjuvant Therapy: Major Pathologic Response and Its Clinical Significance.

Am J Surg Pathol. 2025-6-1

[6]

Predicting axillary residual disease after neoadjuvant therapy in breast cancer using baseline MRI and ultrasound.

Eur Radiol. 2025-2-8

[7]

Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: a meta-analysis.

BMC Cancer. 2025-1-22

[8]

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2- breast cancer-FINEST study.

Cancer Commun (Lond). 2025-4

[9]

The Role of the NOLUS Score in Predicting pCR and iDFS in HR-positive HER2-negative Early Breast Cancer Patients who Received Neoadjuvant Chemotherapy.

Cancer Diagn Progn. 2024-11-3

[10]

Challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the American College of Radiology (ACR), the Sarah Cannon Research Institute, and the American College of Radiation Oncology (ACRO).

Lancet Oncol. 2024-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Pathological complete response and accelerated drug approval in early breast cancer.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

引用本文的文献